Skip to content Skip to footer
Subscribe Now
NEWS

Earendil Labs and Sanofi Forge ~$2.56B Deal to Advance Bispecific Antibodies for Autoimmune Diseases

Shots: Earendil Labs has entered into a strategic collaboration with Sanofi to advance bispecific candidates for autoimmune & inflammatory diseases using Earendil's discovery platform Under the deal, Earendil Labs will identify & optimize bispecific antibody candidates for autoimmune & inflammatory disease targets, while Sanofi will handle the development & worldwide commercialization of the products As…
January 5, 2026

Read more

TOP 20

20 AI Healthcare Companies of 2025  

Shots:  AI is revolutionizing healthcare, reshaping drug discovery, protein design, and precision therapeutics. Companies are now tackling previously “undruggable” targets and moving treatments through development pipelines faster than ever  The AI in the healthcare market is exploding. From a valuation of $26.57B in 2024, it is projected to reach $505.59B by 2033, growing at a CAGR of 38.8%. This rapid…
December 18, 2025

Read more

Sanofi
NEWS

Sanofi Enters a ~$1.84B Global License Agreement with Earendil Labs for HXN-1002 & HXN-1003

Shots: Earendil Labs has granted Sanofi exclusive global rights to develop HXN-1002 & HXN-1003 bispecific antibodies for autoimmune & inflammatory bowel diseases As per the deal, Earendil Labs will receive $125M upfront, ~$1.72B in development & commercial milestones, incl. a near-term $50M payment, & tiered royalties ranging from high-single to low-double digits Developed using Earendil…
April 17, 2025

Read more